The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 1 dose-escalation trial using convection-enhanced delivery of radiolabeled monoclonal antibody for diffuse intrinsic pontine glioma following external radiation therapy.
 
Mark M. Souweidane
No Relationships to Disclose
 
Kim Kramer
Consulting or Advisory Role - YmAbs Therapeutics Inc
 
Neeta Pandit-Taskar
Honoraria - Actinium Pharmaceuticals; AstraZeneca/MedImmune
Consulting or Advisory Role - Illumina; progenics
Speakers' Bureau - Actinium Pharmaceuticals
Research Funding - Bayer Health; Bristol-Myers Squibb; Clarity Pharmaceuticals; Imaginab; Janssen; Regeneron
Travel, Accommodations, Expenses - Bayer
 
Sofia Haque
Honoraria - Advance Medical
Consulting or Advisory Role - Advance Medical
 
Pat Zanzonico
No Relationships to Disclose
 
Jorge A. Carrasquillo
Consulting or Advisory Role - regeneron; Y-mAbs Therapeutics; Y-mAbs Therapeutics
Research Funding - regeneron
 
Serge K. Lyashchenko
Leadership - Evergreen Theragnostics
Stock and Other Ownership Interests - Evergreen Theragnostics
Consulting or Advisory Role - Clarity Pharmaceuticals; Evergreen Theragnostics; Evergreen Theragnostics; Ymabs Therapeutics Inc
 
Sunitha B Thakur
No Relationships to Disclose
 
Yasmin Khakoo
No Relationships to Disclose
 
Maria Donzelli
No Relationships to Disclose
 
Jason Stuart Lewis
Leadership - pHLIP
Stock and Other Ownership Interests - Evergreen Theragnostics; pHLIP; Summit Biomedical Imaging; Telix Pharmaceuticals
Consulting or Advisory Role - Clarity Pharmaceuticals; Invicro; TPG Capital; Varian Medical Systems
Research Funding - Curadel; Lilly; MabVax; Merck
Patents, Royalties, Other Intellectual Property - Elucida Oncology, Inc; Macrocyclics, Inc; Theragnostics, Ltd
Travel, Accommodations, Expenses - CSRA; CSRA
 
Nai-Kong V. Cheung
Stock and Other Ownership Interests - Abpro; Eureka Therapeutics; Ymabs Therapeutics Inc
Consulting or Advisory Role - Abpro; Eureka Therapeutics
Research Funding - Abpro (Inst); Ymabs Therapeutics Inc (Inst)
Patents, Royalties, Other Intellectual Property - 30. Heterodimeric tetravalency and specificity antibody compositions and uses thereof (HDTVS) (Inst); A N-acetylgalactosamino dendron-clearing agent for DOTA-pretargeted radioimmuno-therapy (Inst); A33 - C825 conjugate for Pretargeted Radioimmunotherapy and application as a theranostic product (Inst); affinity matured hu8H9 (Inst); Anti-A33 Antibodies and Uses Thereof (Inst); Anti-CD3 antibodies and uses thereof40. Anti-CD3 antibodies and uses thereof (Inst); Anti-CD33 antibodies for treating cancer (Inst); Anti-CD33 antibody agents (Inst); anti-chondroitin sulfate proteoglycan 4 antibodies and uses thereof (Inst); anti-GD2 antibodies (Inst); Anti-GD2 antibodies and uses thereof (Inst); Anti-GD2 SADA conjugates and uses thereof (Inst); Anti-Glypican 3 antibodies and uses thereof (Inst); Anti-KIR3DL1 antibodies (Inst); Anti-L1-CAM Antibodies and Uses Thereof (Inst); Anti-polysialic acid antibodies and uses thereof (Inst); Anti-STEAP-1 antibodies and uses thereof (Inst); bispecific HER2 and CD3 binding molecules (Inst); CD19 antibodies and methods of using the same (Inst); CD22 antibodies and methods of using the same (Inst); CD33 antibodies and methods of using the same to treat cancer (Inst); Dectin-1 (CLEC7A) single nucleotide polymorphism as a biomarker for predicting antibody response when using b-glucan as a vaccine adjuvant (Inst); DOTA BsAb for new Humanized next generation anti-GPA33 antibodies with Fc-enhanced function or bispecific properties (Inst); GD2 peptide mimics (Inst); generation and use of HLA-A2–restricted peptide-specific mAbs and CARs (Inst); Herceptin - C825 conjugate for Pretargeted Radioimmunotherapy and application as a theranostic product (Inst); high-affinity anti-GD2 antibodies (Inst); methods for detecting MRD (Inst); methods for preparing and using scFv (Inst); Methods of enhancing immunogenicity of poorly immunogenic anti-specific vaccines using oral yeast beta-glucans (Inst); Modular self assembly disassembly (SADA) technologies (Inst); Multimerization of IL-15/IL-15R alpha complexes to enhance immunotherapy (Inst); multimerization technologies (Inst); Multimodal fluorine-Cy3/5/7-DOTA-hapten compositions, diagnostics, fluorescence guided surgery and radioimmunotherapy (Inst); ROR2 antibodies (Inst); scfv constructs of anti-GD2 antibodies (Inst); Small Molecule Hapten Chelates for Pretargeted Radioimmunotherapy with Anti-DOTA(lanthanide) Bispecific Antibodies (Proteus) (Inst); T cell receptor-like antibody agents specific for EBV latent membrane protein 2A peptide presented by human HLA (Inst); therapy-enhancing glucan (Inst); use of mAb 8H9 (Inst)
Travel, Accommodations, Expenses - Partners Therapeutics
 
Steven M. Larson
Stock and Other Ownership Interests - Elucida Oncology; Ymabs Therapeutics Inc
Consulting or Advisory Role - miscellaneous see below; Prescient Therapeutics
Research Funding - Regeneron; Wilex; Ymabs Therapeutics Inc
Patents, Royalties, Other Intellectual Property - Antigen-Specific Composition and In Vivo Methods for Detecting and Localizing an Antigenic Site and for Radiotherapy. Larson SM, Finn R, Carrasquillo JA, Reynolds JC, Neumann RD, Graham MC, Pentlow KS. U.S. Patent No. 5,185,142. Date: Feb. 9, 1993.; Multi-Specific Antibodies with Affinity for Human A33 Antigen and DOTA Metal Complex and Uses Thereof . Cheal S, Hong Xu, Larson SM, NK Cheung. US Patent No. 62,113,988. Date 2/09/2015.; Non-invasive imaging and Quantification of Specific Antigen and Uses Thereof. Smith-Jones, P and Larson SM. Provisional Patent Application. Registration Number 28,325. Date 1/06/03.; Single chain Fv polynucleotide or peptide construct of anti-ganglioside GD2 antibodies, cells expressing same and related methods NK Cheung, SM Larson, HF Guo, K Rivlin, M. Sadelain US Patent No. 6,451,995.; Small-Molecule HSP90 Inhibitors, Chiosis, Gabriela; Huazhong He, Llauger-Bufi, Laura; Kim Joungnam; Larson, Steve; Smith-Jones, Peter. US Patent No. 7,834,181. Date 11/16/10.; Synthesis and Utilization of 17-methyl and 17-cyclo-propylmethyl-3, 14-Di-hydroxy-4, 5-Epoxy 6 b-Fluoromorphines (Foxy and cyclofoxy) as (18F)-labeled opiate ligands for positron emission transaxial tomography. (PET) Rice KC, Pert CB, Burke TR, Jr., Larso; Systems and Methods for Determining Optimum Patient-Specific Antibody Dose for Tumor Targeting. Zanzonico P, Cheal SM, Larson SM, Osborne J, Fung Edward K. US Patent No. 62,165699. Date 5/22/2015
 
John Roemer Nielsen
Employment - YmAbs Therapeutics Inc
Stock and Other Ownership Interests - YmAbs Therapeutics Inc
 
Ira J. Dunkel
Consulting or Advisory Role - Apexigen; AstraZeneca; Bristol-Myers Squibb; Celgene; Day One Therapeutics; Fennec Pharma; QED therapeutics; Roche/Genentech
Research Funding - Bristol-Myers Squibb (Inst); Genentech (Inst); Novartis (Inst)